Sirui(SH:688102) Western Securities·2025-11-06 09:11Investment Rating - The report maintains a "Buy" rating for the company [4][10] Core Insights - The company reported significant growth in its Q3 2025 performance, with revenue reaching 1.174 billion yuan, a year-on-year increase of 21.74%, and a net profit attributable to shareholders of 108 million yuan, up 37.74% year-on-year [1][4] - The company is accelerating its industrial layout to meet the rapid growth demands in various niche markets, including commercial aerospace and medical imaging [2] - The company has made important breakthroughs in high-voltage contact materials and is advancing projects to support the domestic medical imaging equipment industry [2] Financial Performance Summary - For the first three quarters of 2025, the company's revenue was 1.174 billion yuan, with a gross margin of 24.04% and a net margin of 9.58% [1][4] - The Q3 2025 revenue was 402 million yuan, representing an 18.08% year-on-year growth, while the net profit for the quarter was 33.07 million yuan, up 48.07% year-on-year [1] - The company expects EPS for 2025 to be 0.20 yuan, with projected PE ratios of 93.2, 67.4, and 53.9 for 2025, 2026, and 2027 respectively [2][3]